$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000117867020000007 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$99.48M	$33.29M
YoY Change	198.78%	1048.07%
Cost Of Revenue	$13.30M	$3.347M
YoY Change	297.43%
Gross Profit	$86.17M	$29.95M
YoY Change	187.76%
Gross Profit Margin	86.63%	89.95%
Selling, General & Admin	$126.8M	$89.61M
YoY Change	41.46%	23.69%
% of Gross Profit	147.1%	299.22%
Research & Development	$169.6M	$129.1M
YoY Change	31.32%	33.32%
% of Gross Profit	196.78%	431.19%
Depreciation & Amortization	$7.600M	$12.20M
YoY Change	-37.7%	281.25%
% of Gross Profit	8.82%	40.74%
Operating Expenses	$296.3M	$218.7M
YoY Change	35.48%	29.2%
Operating Profit	-$210.2M	-$188.8M
YoY Change	11.32%	28.07%
Interest Expense	$0.00	$7.500M
YoY Change	-100.0%	29.31%
% of Operating Profit
Other Income/Expense, Net	$28.51M	$7.568M
YoY Change	276.74%	23.48%
Pretax Income	-$181.6M	-$181.2M
YoY Change	0.24%	28.27%
Income Tax	$575.0K	$695.0K
% Of Pretax Income
Net Earnings	-$182.2M	-$181.9M
YoY Change	0.17%	28.82%
Net Earnings / Revenue	-183.18%	-546.39%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.617M	-$1.726M
COMMON SHARES
Basic Shares Outstanding	112.6M shares	106.3M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.304B	$1.245B
YoY Change	4.79%	-20.63%
Cash & Equivalents	$467.8M	$725.0M
Short-Term Investments	$836.3M	$519.6M
Other Short-Term Assets	$98.70M	$81.70M
YoY Change	20.81%	22.49%
Inventory	$68.30M	$32.00M
Prepaid Expenses
Receivables	$75.57M	$33.80M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.585B	$1.392B
YoY Change	13.85%	-17.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$429.8M	$568.1M
YoY Change	-24.34%	181.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.03M	$53.90M
YoY Change	-64.69%	53.13%
Total Long-Term Assets	$694.9M	$622.0M
YoY Change	11.71%	161.56%
TOTAL ASSETS
Total Short-Term Assets	$1.585B	$1.392B
Total Long-Term Assets	$694.9M	$622.0M
Total Assets	$2.280B	$2.014B
YoY Change	13.19%	4.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.48M	$22.70M
YoY Change	78.34%	71.97%
Accrued Expenses	$183.2M	$123.9M
YoY Change	47.88%	94.2%
Deferred Revenue	$86.04M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$338.8M	$149.2M
YoY Change	127.07%	29.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$30.00M
YoY Change	-100.0%	0.0%
Other Long-Term Liabilities	$9.198M	$287.9M
YoY Change	-96.81%	1151.74%
Total Long-Term Liabilities	$9.198M	$317.9M
YoY Change	-97.11%	499.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$338.8M	$149.2M
Total Long-Term Liabilities	$9.198M	$317.9M
Total Liabilities	$929.9M	$467.0M
YoY Change	99.12%	177.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.909B
YoY Change
Common Stock	$5.291B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.350B	$1.547B
YoY Change
Total Liabilities & Shareholders Equity	$2.280B	$2.014B
YoY Change	13.19%	4.73%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$182.2M	-$181.9M
YoY Change	0.17%	28.82%
Depreciation, Depletion And Amortization	$7.600M	$12.20M
YoY Change	-37.7%	281.25%
Cash From Operating Activities	-$246.2M	-$188.5M
YoY Change	30.58%	21.1%
INVESTING ACTIVITIES
Capital Expenditures	$19.62M	$44.05M
YoY Change	-55.47%	107.22%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$146.7M
YoY Change	-100.0%	-229.14%
Cash From Investing Activities	$113.7M	$102.7M
YoY Change	10.75%	-176.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$381.9M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$53.87M	$390.9M
YoY Change	-86.22%	841.5%
NET CHANGE
Cash From Operating Activities	-$246.2M	-$188.5M
Cash From Investing Activities	$113.7M	$102.7M
Cash From Financing Activities	$53.87M	$390.9M
Net Change In Cash	-$79.24M	$305.1M
YoY Change	-125.97%	-222.54%
FREE CASH FLOW
Cash From Operating Activities	-$246.2M	-$188.5M
Capital Expenditures	$19.62M	$44.05M
Free Cash Flow	-$265.8M	-$232.6M
YoY Change	14.28%	31.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2019Q1	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36407
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street,
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2020Q1	dei	City Area Code CityAreaCode	617
CY2020Q1	dei	City Area Code CityAreaCode	617
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	551-8200
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2020Q1	dei	Trading Symbol TradingSymbol	ALNY
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	114819151	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	467779000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	547178000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	836346000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	975017000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	38078000	USD
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	13967000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	75572000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	43011000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	68300000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	56348000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	98698000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	80343000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	1584773000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1715864000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	429814000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	425179000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	221280000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	221197000	USD
CY2020Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	24725000	USD
CY2019Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	14825000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19032000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18069000	USD
CY2020Q1	us-gaap	Assets Assets	2279624000	USD
CY2019Q4	us-gaap	Assets Assets	2395134000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	40484000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	49884000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	183221000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	197201000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	29043000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27688000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	86043000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	77821000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	338791000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	352594000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	275782000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	276135000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	306124000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	318383000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9198000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9330000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	929895000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	956442000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	113168000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	113168000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112188000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112188000	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	1131000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1122000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5289966000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5201176000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-32059000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36518000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3909309000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3727088000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1349729000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2279624000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2395134000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	99476000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33294000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13302000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3347000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	169571000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	129127000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	126761000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89608000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	309634000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	222082000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-210158000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-188788000	USD
CY2020Q1	us-gaap	Investment Income Net InvestmentIncomeNet	5480000	USD
CY2019Q1	us-gaap	Investment Income Net InvestmentIncomeNet	7525000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23032000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	43000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28512000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7568000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181646000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181220000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	575000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	695000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-181915000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.62
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.73
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112748000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105400000	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-181915000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4045000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	360000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	340000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-74000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-177762000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181555000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1438692000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	54221000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34578000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-182221000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1349729000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1301965000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11409000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	-58000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	784000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32541000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	360000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-181915000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1546986000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-182221000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-181915000	USD
CY2020Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	7613000	USD
CY2019Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	3838000	USD
CY2020Q1	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	9393000	USD
CY2019Q1	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	10255000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	34578000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	32032000	USD
CY2020Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	24111000	USD
CY2019Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	660000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-1075000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32882000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	15041000	USD
CY2020Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0	USD
CY2019Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-12386000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11952000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7134000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19958000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8988000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14215000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-24332000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4030000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-834000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9036000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	7702000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-246161000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-188510000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19617000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44049000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	396409000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	256996000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	539614000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	403697000	USD
CY2020Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	9900000	USD
CY2019Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	113688000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	102652000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	53869000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	9031000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381900000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	53869000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	390931000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-631000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-79235000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	305073000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	549628000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	422631000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470393000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	727704000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6619000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13033000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2939000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2018, we received approval for ONPATTRO from the United States Food and Drug Administration, or FDA, and began commercializing and generating product revenues in the U.S., and also received marketing authorization for ONPATTRO from the European Commission, or EC. As of March 31, 2020, we have launched ONPATTRO in the U.S., Europe, Japan and in several additional countries. In November 2019, we received approval for GIVLAARI from the FDA and began commercializing and generating product revenues in the U.S. in December 2019. In March 2020, we received marketing authorization for GIVLAARI from the EC, and in April 2020, we launched GIVLAARI in Germany. Regulatory filings in additional markets are pending or planned for 2020 and beyond for both products.</span></div>
CY2020Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Reclassification</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div>
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	968656000	USD
CY2020Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	25970000	USD
CY2019Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	14929000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	152829000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	153117000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14678000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	928000	USD
CY2020Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	30662000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	15418000	USD
CY2020Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	33412000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	38275000	USD
CY2020Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4226000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2655000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	68300000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	56348000	USD
CY2019Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4516000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	334000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	972838000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1315012000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	246000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	109000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1315149000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	136492000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	340132000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	836346000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	975017000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	972838000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1315149000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	467779000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	724959000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	167000	USD
CY2019Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	439000	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2447000	USD
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2306000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	470393000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	727704000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	1657000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	346000	USD
CY2019Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-14000	USD
CY2020Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-2802000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4459000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	360000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	77.50
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5600000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34578000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32032000	USD
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15020000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14585000	shares

Files In Submission

Name	View Source	Status
0001178670-20-000007-index-headers.html	Edgar Link	pending
0001178670-20-000007-index.html	Edgar Link	pending
0001178670-20-000007.txt	Edgar Link	pending
0001178670-20-000007-xbrl.zip	Edgar Link	pending
alny-20200331.htm	Edgar Link	pending
alny-20200331.xsd	Edgar Link	pending
alny-20200331_cal.xml	Edgar Link	unprocessable
alny-20200331_def.xml	Edgar Link	unprocessable
alny-20200331_g1.jpg	Edgar Link	pending
alny-20200331_g2.jpg	Edgar Link	pending
alny-20200331_htm.xml	Edgar Link	completed
alny-20200331_lab.xml	Edgar Link	unprocessable
alny-20200331_pre.xml	Edgar Link	unprocessable
alnyq1202010-qex311.htm	Edgar Link	pending
alnyq1202010-qex312.htm	Edgar Link	pending
alnyq1202010-qex321.htm	Edgar Link	pending
alnyq1202010-qex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2020 Q1 Form 10-Q Financial Statement

#000117867020000007 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2020 Q1 Form 10-Q Financial Statement

#000117867020000007 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny